Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

May 18, 2015
Sangamo BioSciences Presents New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storge Disorders at Annual Meeting of the American Society of Gene and Cell Therapy

May 14, 2015
Sangamo BioSciences Provides Clinical Update On SB-728-T Program and Developments In Other ZFP Therapeutic Programs at American Society of Gene and Cell Therapy Annual Meeting


View all »Events & Presentations

Jun 22, 2015 at 9:00 AM PT
2015 Annual Meeting of Stockholders

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
12.17
Change:
- 0.28
Day High:
12.57
Day Low:
12.16
Volume:
754,100
4:00 PM ET on May 22, 2015

Shareholder Tools